<DOC>
	<DOCNO>NCT00287859</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , topotecan , work different way stop growth tumor cell , either kill cell stop dividing . Chemotherapy drug may different effect patient poor performance status . PURPOSE : This phase I trial study side effect best dose topotecan treating patient progressive recurrent ovarian epithelial , fallopian tube , primary peritoneal cavity cancer poor performance status .</brief_summary>
	<brief_title>Topotecan Treating Patients With Ovarian Epithelial , Fallopian Tube , Primary Peritoneal Cavity Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose weekly topotecan patient progressive recurrent ovarian epithelial , fallopian tube , primary peritoneal cavity cancer poor performance status . Secondary - Estimate response rate woman poor performance status use future clinical trial . OUTLINE : This dose-escalation study . Patients receive topotecan intravenously ( IV ) 30 minute day 1 , 8 , 15 , 22 , 29 . Treatment repeat every 42 day 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos topotecan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . A total 6 patient treated MTD . Patients follow periodically 2 year .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Histological diagnosis ovarian epithelial , fallopian tube , primary peritoneal cavity cancer Progressive recurrent disease Received ≥ 1 prior course chemotherapy Measurable evaluable disease OR disease assessable CA 125 , define CA 125 &gt; normal increase 2 reading &gt; 14 day apart Karnofsky performance status 1050 % Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Creatinine ≤ 1.5 mg/dL Alkaline phosphatase ≤ 3 time upper limit normal ( ULN ) Total bilirubin ≤ 1.5 time ULN SGOT ≤ 3 time ULN Life expectancy ≥ 12 week Not pregnant nursing Negative pregnancy test Fertile patient must use accepted effective nonhormonal contraception Other neoplasm within past 5 year except nonmetastatic , nonmelanoma skin cancer , carcinoma situ cervix , cancer cure surgery chemotherapy Septicemia , severe infection , acute hepatitis Severe gastrointestinal bleeding , define require blood transfusion hospitalization</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>fallopian tube cancer</keyword>
	<keyword>peritoneal cavity cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
</DOC>